3. Novavax (NVAX) is a clinical-stage biopharmaceutical company developing recombinant vaccines. Using advanced proprietary virus-like particle (VLP) technology, Novavax develops novel vaccines to treat a broad range of infectious diseases worldwide, including H1N1.
The company's future performance is expected positive, based on its funding and licensing deals. In February, the company secured a three-year flu-vaccine contract valued $97 million from the U.S. government. Sources say the contract could be extended for another two years raising the total value by $82.1 million.
Meanwhile, the company announced entering a licensing agreement with LG Life Sciences (LGLS) of South Korea, for using its vaccine technology in South Korea and other countries. The company is expected to receive an undisclosed, upfront and milestone payment from LGLS, in the form of royalty payments from commercial product sales. Also, the HHS Biomedical Advanced Research and Development Authority (BARDA) of the U.S. awarded Novavax a three-year contract worth $97 million with an option to extend it by two additional years, carrying a potential contract value of $179.1 million.All the four analysts covering the stock recommended a buy rating on it. The stock's average 12-month price target is $6.3, which is 137.6% higher than the stock's current price, as per analysts surveyed by Bloomberg.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV